Raute recently issued another positive profit warning, according to which FY’25 revenue will be slig...
Redeye comments on CTEK’s Q3 report, which showed weaker growth than expected, but this was compensa...
Redeye provides its initial take on Hansa Biopharma’s Q3 report.
Redeye updates on Better Collective ahead of Q3-results (due 12 November after market close) where w...
Dovre’s losses continued over Q3, as was known thanks to the yet another negative profit warning.
Redeye reviews BioInvent's Q3 report 2025. The company is doubling down on BI-1206 and BI-1808.
Suominen's Q3 headline figures had been pre-announced in conjunction with the profit warning on 15 O...
Fastighetsbolaget Prisma Properties fortsätter att överträffa förväntningarna med en imponerande res...
Etteplan issued a profit warning yesterday alongside preliminary Q3 figures.
Redeye presents its preview for Devyser’s Q3 2025 report, due on November 5.
Solteq’s Q3 fell slightly short of our expectations.
Dovre issued another negative profit warning earlier this month and then disclosed Q3 EBIT to be abo...
Redeye provides an initial take following Senzime’s Q3 2025 report.
Hanza ökade omsättningen med 27 procent till 1 401 mkr, varav 2 procent organiskt.
Redeye updates its production estimates for Arise ahead of its Q3 report, which is due on 6 November...
Aspo sold its Leipurin segment at a relatively good price in Q3 2025.
Redeye provides an update following Truecaller’s Q3 2025 report, which came in below expectations du...
* More margin gains, 12% target now looking conservative * Adj.
* Adj. EBITA SEK 274m (+4% vs. ABG, +2% vs. IR consensus) * We expect consensus adj.
Marimekko is set to report Q3 figures on Friday, October 31.
